Novartis AG Increase Decrease Through Exercise Of Options
Novartis AG (NVSEF) reported Increase Decrease Through Exercise Of Options of -$1.00 million for the 3-month period ending 2024-06-30, per its 6-K filed 2025-07-17.
Financial Statements › Notes
ifrs-full:IncreaseDecreaseThroughExerciseOfOptions · last filed 2026-02-04
- Novartis AG increase decrease through exercise of options for the quarter ending 2024-06-30 was -$1.00M.
- Novartis AG increase decrease through exercise of options for the quarter ending 2022-06-30 was -$2.00M.
- Novartis AG increase decrease through exercise of options for the quarter ending 2021-06-30 was -$3.00M.
| Period end | Increase Decrease Through Exercise Of Options 3 month | Increase Decrease Through Exercise Of Options 6 month | Increase Decrease Through Exercise Of Options 12 month |
|---|---|---|---|
| 2024-06-30 | -$1.00M 6-K · filed 2025-07-17 | -$35.00M 6-K · filed 2025-07-17 | |
| 2023-12-31 | $146.00M 20-F · filed 2026-02-04 | ||
| 2023-06-30 | $153.00M 6-K · filed 2024-07-18 | ||
| 2022-12-31 | $88.00M 20-F · filed 2025-01-31 | ||
| 2022-06-30 | -$2.00M 6-K · filed 2023-07-18 | $91.00M 6-K · filed 2023-07-18 | |
| 2021-12-31 | $39.00M 20-F · filed 2024-01-31 | ||
| 2021-06-30 | -$3.00M 6-K · filed 2022-07-19 | $39.00M 6-K · filed 2022-07-19 | |
| 2020-12-31 | $806.00M 20-F/A · filed 2023-05-15 | ||
| 2020-06-30 | $823.00M 6-K · filed 2021-07-21 | ||
| 2019-12-31 | $210.00M 20-F · filed 2022-02-02 | ||
| 2019-06-30 | $200.00M 6-K · filed 2020-07-21 | ||
| 2018-12-31 | $434.00M 20-F · filed 2021-01-26 | ||
| 2018-06-30 | $433.00M 6-K · filed 2019-07-18 | ||
| 2017-12-31 | $255.00M 20-F · filed 2020-01-29 |